A warm welcome everyone to Cellink's First Digital Capital Markets Day. We're truly happy to host this virtual meeting and connecting with all of you around the globe. We look forward to share insights on our bioconvergence agenda and our road ahead. Here's the agenda for today. As you can see, you will meet external speakers as well as members of Team Cellink. We'll spend time on the future of medicine, product development, our results for the Q1, and our customers. You'll also get to know our business areas, Biosciences, Bioprinting, and Industrial Solutions. you can find the agenda and time slots on cellink.com, the investor section. Before we start, I'd like to highlight a couple of things. If you look to the right, you can see the control panel. There you can adjust your audio setting and your screen size. If you have any technical questions, send them to the question box. If we move on to the next slide. Our last session for today will be the Q&A session. Participate by sending your questions to the question box. By that, I think it is time to begin. Let us present the first speaker for today, Dr. Robert Langer, MIT, co-founder of Moderna, and scientific advisor to Cellink's Scientific Advisor Board. Dr. Langer is one of history's most prolific inventors in medicine. He has received over 220 major awards, written over 1,500 articles, and filed for over 1,400 patent applications worldwide, of which 900 have been granted. He will now present the future of medicine. Please go ahead, Dr. Langer. Well, thank you so much. I'm really delighted to be able to speak with you today. I was asked to try to address three things. First, why I decided to join Cellink as a scientific advisor. Two, what was just mentioned, some of the healthcare challenges of today. Three, how Cellink can play a role in that. First, I've had actually a significant history with Cellink, even when it was a much smaller company. Starting in 2017, Erik talked to me, and we were doing a number of projects in what's called tissue engineering. That's actually an area that pretty much started in our lab and Jay Vacanti's lab, my collaborator, to make new tissues and organs. One of the things that we were working on with Children's Hospital was creating new biomimetic heart valves. We were also working on artificial pancreas. These are problems that affect many, many patients, millions of patients around the world. What Cellink was kind enough to do was provide their bioprinters to us. What was also very important to me was they also provided student fellowships to support several of our students who were doing master's and doctoral theses in these areas. That really enabled us to make significant progress. We published a number of papers in this area, and we're moving forward on these to hopefully begin clinical trials. I've also known many of the other scientific advisors on Cellink's Scientific Advisory Board for a number of years. In fact, Ali Khademhosseini, who's one of the advisors, is one of my former PhD students. David Williams, another one of their advisors, actually gave me a honorary degree when he was at the University of Liverpool, from Liverpool. I've known them for a while, and then I've also done some advising to one of the subsidiary Cellink companies as well. I was really delighted when Erik asked me to join their board. I think when you look at what Cellink's doing today, it's really pretty remarkable. They have technologies in Bioprinting, regenerative medicine, 3D culture, drug discovery, diagnostics, cellomics, bioprocessing, biosensors, all kinds of things that are just very helpful to what we and others do. I thought I'd take a few minutes and tell you at least what I think is some of the future areas of medicine. One, clearly to me, is genetic therapies. As was mentioned in the introduction and on the slide, is one of the companies I helped start was Moderna, which is leading the charge, or one of the companies leading the charge in messenger RNA therapeutics. That's been leading to vaccines for COVID all over the world. One of the Swedish companies is helping on some of the manufacturing. Another company that I was on the scientific advisory board on from the beginning is Alnylam, which is actually doing almost the opposite of what Moderna is doing. Alnylam is creating small and siRNA, and that's a way of knocking genes down. Both those companies have been incredibly successful, and it's been a pleasure to work with them, too. I also think we're going to see more work on gene editing and new types of RNAs, new types of all kinds of gene editing approaches. The second area that I want to mention is nanotechnology. In fact, one of the key things that maybe a lot of people don't realize is nanotechnology is key to genetic therapies. If you just injected messenger RNA by itself into the body, it would just get destroyed. It wouldn't get into cells, so you put them in nanoparticles, and that's been a key way of getting them to work. That's also been true for siRNA, and so I think we'll see delivery technologies like nanotechnology be very important. Not only is nanotechnology important for delivery of these important molecules, it's also been very valuable for creating new technologies. Another company I've been involved with is Seer, which just went public a few months ago, and they're using nanoparticles to determine the proteome. It's like a fingerprint of a person's proteins in their body. There are companies like T2 Biosystems that are using nanotechnology for new diagnostics. The third area that I want to mention are cell therapies. Cell therapies are not only a tissue engineering, which I mentioned before, where you might take a cell, including a stem cell, and bioprint it or put it on a material scaffold to make virtually any tissue or organ, not just heart valves or pancreases, but we're looking at making skin, cartilage, bone, almost everything. Of course, the other big area with cell technology are things like CAR T-cells, which are really creating a revolution in cancer therapies. The fourth area I want to mention is digital medicine. There are companies now like Pear Therapeutics that have digital medicine systems that have actually been approved by FDA, for helping patients with opioid addiction. There's other companies like Akili that are creating video games that can help with children overcome attention deficit disorder, still others, like Luminopia, that are working with Sesame Street characters and Sesame Street to actually help little children with lazy eye and correct their eye rather than wear a Band-Aid over it for months, which they won't do. They can actually now play video games to change that. The final area I was going to mention is artificial intelligence, there are a number of examples of this. In fact, you may know MIT just put in, with donors, $1 billion to create a whole new college of artificial intelligence. You have companies like Google with apps to confirm diseases like diabetic retinopathy remotely. Now, how does Cellink play into all this? Well, I think actually in almost every way they will play into it. One of the things that I've talked about amongst others over the years is the area of convergence. In fact, the Nobel laureate Phil Sharp, who's my colleague at MIT, and I wrote an article in "Science," the Journal of Science in 2011, actually introducing this concept of convergence, and I thought I would just read you a little bit from it. What we basically said is there's been three biomedical revolutions. The first is molecular biology, the second is genomics, the third revolution is what we're calling convergence. What we basically say is the third revolution, convergence, is multidisciplinary thinking and analysis will permit the emergence of new scientific principles, where engineers and physical scientists are equal partners with biologists and clinicians in addressing many of the new medical challenges. I think that's exactly what Cellink is doing. When you look at some of the slides that Erik will show you later, what you'll see is this whole area of bioconvergence is exactly what they're doing. They're involved in artificial intelligence, medical science, gene therapy, new biologics, chemical design, and analyzing big data. One of Erik's slides, which I think epitomizes, and I didn't tell him this or vice versa, is where they call Cellink the bioconvergence company. Again, it goes back to what Phil and I wrote in that Science article. There's probably about 20 different technologies listed on his slide, which he'll show you on Cellink being a bioconvergence company. They include all the things that are really needed to practice all those five areas that I mentioned and many, many more, things like bioprocessing, live cell imaging, microscopy, liquid handling, 3D printing, biosensors. I could go on and on, but he'll do a better job. Those are some of the things that I think will augur incredibly well for Cellink's future. I think what we're seeing is being able to do these things is going to be so important for advancing new therapies, advancing new technologies. It's been amazing what we've witnessed in the biotechnology area over the past few years with companies like Moderna and BioNTech and others, just totally changing the way medicine is practiced. All these actually are startup companies for the most part, just like Cellink is and was. These are not the big companies. These are the smaller companies that have been pioneering these new technologies and really changing the world from it because they are willing to take risks. When you see the growth of these companies and what they're able to do, it's been remarkable. I think what you'll see, and I believe you'll see, is that Cellink will play just a critical role in enabling all kinds of new technologies to happen. The five areas I mentioned, I think will continue to grow and really change the world in remarkable ways by creating new therapies, new tools, and so forth. Thank you very much for listening to me. It's really been an honor and a pleasure to speak to you, and an honor and a pleasure for me to work with Cellink. Thank you so much. Thank you, Dr. Langer, for an inspiring presentation. Our next speaker, if we can move on to the next slide, will now present our bioconvergence agenda and our strategic focus areas. Here is our CEO and co-founder of Cellink, Erik Gatenholm. Thank you so much. Professor Robert Langer was a wonderful start to this great event. I want to, of course, give everybody a very warm and exciting welcome to today's event. It's my absolute pleasure to present our strategic focus for the years to come. I'd like to take a moment, actually, to start by thanking our excellent team, shareholders, investors, and most importantly, of course, our customers around the world for your loyalty to the Cellink Group and the products that we offer. We're honored to have you with us and look forward to, of course, creating the future of medicine together with you. I'd also, of course, like to take a little bit of time and give a special thanks to you, Isabelle, our head of IR, for coordinating and arranging this entire event. It's a pleasure to, in the first time in our history, address all of our wonderful shareholders and investors and listeners around the world. We could not have done it without you. For those of you who don't know me, my name is Erik Gatenholm, Co-founder and CEO at Cellink Group. My background is in business management from Virginia Tech University with a focus on entrepreneurship. I also have an MBA from University of Gothenburg. My passion in life is really the commercialization of life sciences technologies that can disrupt industries and impact markets. I believe the greatest impact I want to do in life is to leave this world a better place by providing technologies that can save lives. With that, I'll present some great things that we are working on, both strategically and operationally, and to ensure that we can, of course, continue to deliver on our customers' needs and on this wonderful mission of ours as a company. You can go to the next slide. To understand our future, let me first tell you a little bit about our past. As a company, our vision and mission is to create the future of medicine by providing technologies, products, and services for our customers to create, understand, and master biology. Our journey started on 27th of January 2016, so just about five years ago, and we're very proud to briefly reflect over the accomplishments that we've achieved so far. Just over the last few years, we've transitioned essentially from being a single product or technology company to a bioconvergence company with about 700 team members, 2,000+ users around the world, customers in more than 65 countries, and with more than 1,700 notable publications describing the great use and the great purpose of our technologies in the market. We're addressing today a market potential of about $150 billion-$200 billion, depending, of course, on the complementary technologies that can be provided in conjunction with our current portfolio. I'm very thankful for the great work our team has done and of course to get us to this point, but I also believe, and I'm very excited about the future that we're going for together. I believe that the most important thing that has been the success factor for us has really been the great culture that we've been able to establish at the company, where ambition is truly celebrated, and Cellink is a place where we can live our core values, which are namely passion, inspiration, and persistence. I believe that these will be the critical aspects that will take us to the next level. You can go to the next slide. To further understand our future, we really need to look at the major challenges that we are tackling on a daily basis. Global health expenditures, they continue to rise dramatically and expected to reach about $10 trillion over the next few years. The main reason behind this is really the increased life expectancy that has led to an aging population alongside increased frequency for chronic diseases such as cancer, heart disease, and diabetes. As we get older, we want to increase our quality of life in addition to that. We don't want to, of course, just live longer, we want to do more things with our lives as we age. Approximately 50% of the population in the U.S. are considered chronically ill, and these patients account for about 85% of the total expenditure of healthcare services. You can go to the next slide. If we look at perhaps the most pressing challenge today, and something that is of most relevant, I believe, and what everybody, of course, is talking about, the global pandemic that we're experiencing is really transforming the healthcare industry in the short term. In a matter of months, we've essentially gone from being very proactive in terms of how we target new diseases or study new diseases, do research in critical areas, to basically battling and fighting local pandemics or global pandemics, and battling the effects of such pandemic. Of course, going from a fully functional global economy to a lockdown pandemic-ridden world, it has been quite unprecedented. A lot of companies, researchers, many of our customers, for instance, they've had to make a transition in the short term to look at essentially how do we battle disease at perhaps an earlier stage. I believe a major challenge for the global healthcare industry at this point is to get to a point where we can discover or understand and detect disease at a much earlier stage. If we understand the underlying drivers behind these pandemics, I believe that we'd be able to tackle them a lot faster and more efficiently. You can go to next slide. In addition to a disease detection identification, I believe we're facing a major challenge when it comes to treatment development. If we just look at the cost of developing new pharmaceutical treatments, it can cost more than $2 billion and take about 12 years to develop one new pharmaceutical drug. The fact is, nine out of 10 of these drugs, they fail in the clinical stages of the development, meaning that these pharma companies, they spend billions of dollars to get these drugs through early stage toxicology testing, the discovery process, pre-clinical testing, and then in the final stage of the clinical trials, these compounds, they don't make it to the patient. Of course, the vastly increase in expenditures associated with the developing these new drugs, is hampering the outcomes and the treatments. In fact, the increase in costs associated with the development of new drugs has shown no significant growth in the number of new drugs being released, that's a very concerning statement. You can go to next slide. Another important challenge, obviously, one that is very close to us and our founding principles, is that one life is lost essentially every single hour of the day from the lack of organ transplants. In fact, with a 50% rejection rate, it makes the situation even more grave. We see that the shortage of supply in organs and tissues is going to be a major bottleneck for healthcare in the future. As, again, with this growing and with this aging population, we need to find ways to address these challenges. You can go to next slide. We believe that the answer and the solution to these questions and these major challenges really lays in the combination of innovative modern technologies in the field of biology. As Professor Langer was mentioning and talking about was really this bioconvergence concept, where a lot of new multidisciplinary industries and technologies, they converge for the sake of improving the outcomes of biological research and biological treatments. These technologies that we're talking about are on the cutting edge, providing new ways and methods of approaching health challenges because they let us gather more and better data, and with that data, we can tackle healthcare challenges faster and even become more personalized in these treatments and approaches. You can go to next slide, please. Worth mentioning is, of course, the different technologies that come into play in this. As we see here, we're looking at the lower start from the 20th century, we're coming in with a lot of data, especially on the big data side, a lot of computing, machine learning, AI, and a lot of ways that we work with the collection and deciphering of this data. Of course, looking into the future, what we believe is going to be an important aspect, also as what Professor Langer mentioned, really the genetic therapies, looking at digitization of the biological data, the development and manufacturing of biologic drugs, of course, in addition to that, looking into being more proactive through better diagnostics at earlier stages. We see that all of these technologies advancements, they come together, and this is really what creates the bioconvergence and the beauty of it. I will speak about this shortly as well, but to cure cancer or to solve these major healthcare challenges, we really have to approach these from a very different perspective, and no longer are single technology or single product the solution to these type of challenges. You can go to next slide, please. Worth mentioning is, of course, the latest Bio Revolution report that came out just a few days ago, by McKinsey. The report is defining a $2 trillion-$4 trillion market potential for the coming decades in terms of research in areas and application of biomolecules, biosystems, biomachine interface, and biocomputing. I'm very proud and honored to say that Cellink is today not only present within all of these areas with some sort of technology or products, but we're actually leading much of the work in specifically the biosystems area. I highly recommend the report for all the participants. It shines a light on the potential for the future medical applications, and it's a wonderful description of what the potential for bioconvergence is for the next coming decades. You can go to next slide, please. When looking at these areas more specifically, we see how Cellink is actually working today with bioconvergence and in which areas we are currently approaching our customers with products and which areas we see ourself growing in the future and that we need to add to our wonderful portfolio. When we look at these areas, for instance, drug discovery, 3D cell culturing, and regenerative medicine have been areas that we've been approaching for the last five years through our Bioprinting business. Also through many of the acquisitions we've done, we've been able to open up more for biopharmaceuticals, even approach markets with CRISPR technologies or gene editing. Now, of course, with the addition of Scienion and Ginolis, we have been able to start approaching the diagnostics and the biological sensors market. I know we will cover these areas in more detail in the coming presentations from our colleague, Holger and Jonas. You can go to next slide. With that being said, our journey was really started based on the fact that we wanted to conquer the bioprinting market by being the first complete package solution provider. When we entered the market a few years ago, we noticed that first of all, there were no cost-effective printers that could really penetrate the market and open up the field for researchers and scientists. Second of all, there were no universal bioink or reproducible materials that could be used for the bioprinting process. What we did is we opened up that market by providing cost-effective, complete package solutions that would answer to a lot of immediate needs from customers in the bioprinting field. What we also learned to do through many, many journeys and travels to our customer sites is that we started to understand the concept of a bigger picture and really start to map out the other things that our customers are asking for. It's very important to mention this because the mapping of these technologies and products that our customers were craving for, they were either too difficult for them to acquire from someone else, or they were too expensive, or they were simply not available. With our brilliant engineers, researchers, and product developers, we managed to essentially start developing some of these solutions and products that have now become a larger part of our product portfolio and our offering. What's worth mentioning, of course here too is all of this knowledge that we've learned and the need from our customer has really come from just listening to them and understanding them and the work that they are doing. Initially with the bioprinters, which led to the need for liquid handling. The liquid handling led for a need in better reagents management, printing of cells, et cetera, et cetera, and led to a bigger picture. You can go to next slide, please. After several essentially successful product developments along with strategic acquisition, and it's worth mentioning here, our agenda or strategy as a company is not to acquire companies per se, but our agenda and strategy is really to go after the technologies and areas that our customers are asking for. If enough of our customers are saying, "Well, we want to see more products in 3D imaging," or, "We want to see more in live cell imaging," it's our duty to serve these customers and serve their needs, and do that by providing the technologies that are needed, offer great customer care and support, and offer application support that understands the language that our customers are saying. That has been a critical part of our growth success. If we're looking at these business areas, we essentially have had the opportunity to structure ourselves according to these three main business areas. These business areas they really have to do with our vision and mission as a company. The first area is about disease and tissue modeling. This is Bioprinting, where we work with novel technologies to create biological structures using cells, materials, and to use these materials or printed tissues for drug discovery purposes and future for therapies or for treatments. The second business area is Biosciences, where we focus heavily on disease and tissue analysis, and essentially offer products and technologies that can improve the way that we analyze different cell structures or different cells and use for different assays, or for understanding them in drug discovery processes, or even for omics, both genomics, proteomics, and specifically on the sample preparation side. The last business area that was added quite recently Industrial Solutions, where we work a lot with disease and tissue diagnostics. In this business area, it's all about mastering biology because what we want to do is we want to provide technologies that can help us and our customers understand disease at an earlier stage, help diagnose disease in patients at an earlier stage, and that will of course lead to the solution being brought to the market much faster. You can click on the next. More specifically, we're looking essentially at four main areas that together create about $150+ billion market opportunity. The market opportunity is realistically up more towards $200 billion with complementary products that are being offered between these business areas. Let's start with these main four pillars that we offer. The first market is really the tissue engineering market that is expected to reach about $30 billion by 2027. It's a market growing at about 14%, and it's a market where we will continue to provide the latest products and technologies, and again, to provide these products and technologies for tissue creation, and disease creation that can be used later then for different toxicology testing, and then hopefully in the future for therapies and treatments. The second area, or the second fundamental pillar in the market that we're approaching is really the cell line development market. This is a $12 billion market in 2027. Also growing at a double-digit rate. Also, of course, very interesting since many of the new pharmaceutical treatments and compounds coming out or being researched are going to be biologics. This is where we see many of our products being approached and provided to. The third one is single-cell omics market, which is expected to reach about $6.5 billion by 2027. Also a double-digit growing market. Very exciting one. We see ourselves continue to provide excellent technology, especially on the sample preparation side with our great i.DOT system, and even use some of our single-cell sorting devices to approach this market. Lastly, of course, it's the massive diagnostics market of about $103 billion, and growing at a single-digit rate. Nevertheless, it's an important market to approach. You've seen how much that market and these technologies and products have made a difference in the last just 12 months. You can go to the next slide, please. Something worth mentioning here, something that is important to mention is, of course, while we have these wonderful three business areas operating with great technologies that can provide revolutionary ways of doing research and develop new products and treatments, it's also worth mentioning what's going on between these areas. Things are typically not as silos. You can't see things as being very locked in. What we do at Cellink is we've created a lot of workflows, and this is what we call the era of workflow, where we can truly build in ways of working with a wide range of technologies that can answer larger customer questions. For instance, one of the bioconvergence workflows that we're working on is where a patient could be coming into a hospital. This patient would be either carrying a digital diagnostic sensors that could read off their personal data through sweat or blood. This data could potentially show that something is a little bit off. This patient will come to the hospital. The hospital will take a sample, a blood sample, or do a lot of cell analysis. This cell analysis could potentially lead to a diagnosis of cancer in a horrible case, of course. Being able to harvest these cancer cells from a patient's tumor, bring them into a laboratory, sort these cells using our single-cell isolation system or sorting products, expand these cells using our CELLCYTE X system, and see the growth and proliferation of these cells. Take these cancer cells, put them into a bioink, print those cancer tumors out. These are patient-specific cancer tumors. Run these tumors through a high-throughput screening method or a high-throughput screening workflow, dispense either new compounds or very well-known compounds to work on these types of cancer cells. Continue with live cell imaging analysis and understand the efficacy of these drugs that have been dispensed on these cancer tumors. Already there, we're providing a very new type of workflow that enables us to study the efficacy of drugs on patient-specific cancer tumors. Of course, if these are well-known treatments, then we can move forward to provide a personalized treatment plan for the patient, with the right dosage and with the right, of course, medicine. If it's unknown treatments, well this could lead to a new drug discovery. It could go through, of course, efficacy testing, clinical trials, and then provide this treatment for the patient. You can go to next slide, please. Something I think worth mentioning here is this work is ongoing, and it's something that our customers are doing on a daily basis. I want to shine some light on research going on at this very well-known university hospital in Milan. It's the San Raffaele Hospital, where our great colleague, or our great customer, Professor Cristina Scielzo, a leading researcher at San Raffaele, has been working with 3D bioprinting for a few years and actually recently published this very impressive paper on how she's working with patient-specific chronic lymphocytic leukemia cells. These are the most common leukemia cells, or leukemia cancer in the Western world. It's a very relevant study. Professor Scielzo was essentially running this workflow, taking patient-specific cancer tumors, printing these cancer tumors out, and then running through different analysis on these cancer tumors to understand what drives them. I think something very important to mention here is this will allow for a more reliable study of molecular and cell interactions occurring in normal and neoplastic conditions, and could be exploited for clinical purposes to test individual responses to different drugs. That's something that is in the works, and we're very proud to offer these types of technologies to our customers, and something that we see ongoing all around the world. I highly recommend you reading that study because it gives you great insight to what the bioconvergence technology is all about. You can go to next slide, please. Looking at our strategic focus areas for 2021, something which is important for us to position ourselves as a business and, of course, to continue to lead the way forward as a bioconvergence company, is to structure and focus on this very aggressive tech development R&D agenda with a tool of M&A, or being able to acquire companies when needed for strategic purposes. We will, of course, continue to deliver on our financial targets, which is essentially a strong growth agenda where it is all about providing more technologies and equipment and products, reagents to our customers so that they can do their job better. Continue to focus on our customers and being able to deliver the best products and services. In addition to that, we have two exciting areas that I will talk about in just a few minutes. You can go to next slide, please. If we're looking at the first three areas here, really, as I mentioned from the beginning, our agenda is not to acquire companies, but our agenda is to provide technologies that solve our customers' questions and needs. We do that typically in in-house development, very aggressive R&D. If we can acquire something faster and enter a new market, and also at the same time, of course, provide the technology that our customer is asking for, that's the way that we'll go. We've very successfully acquired a few companies in the last 18-24 months. I think that's something that we'll continue to do moving forward if that will help solve our customers' questions. We will, of course, also continue to grow, with about 35% organically for the next year or two. Of course, do that by showing a positive EBITDA. I know Gusten, our colleague here on group level, will tell you a little bit more about how this will be achieved. Lastly, of course, focus heavily on our customers by providing the greatest customer care in the industry, by provide products that are extremely user-friendly, and implement things in the centralized manner where we can both save ourselves time and money, but also save a lot of pain for our customers. You can go to next slide, please. What's worth mentioning is, of course, the customer segments and the wonderful users that we have around the world. If we're looking at, for instance, the academic industry or the academic market, that used to be about 80%-90% of our customer base just a few years ago. Over the last couple of years, we've worked heavier with building up a strong customer base with pharmaceutical and biotech customers around the world. I would like to say we're very proud of seeing all of these great names out there, and we look forward to supporting them over the next coming years. You can go to next slide, please. Something that is of course also going to be extremely important for us moving forward are the partnerships and collaborations that we have established with, for instance, companies like AstraZeneca or Lonza. These partnerships are essential because we're learning more about what our customers or what potential other pharma companies or cell expert companies need to be able to operate more efficiently or to be able to penetrate new markets and provide these patients with better solutions. I would say probably the relationship and the collaboration with Astra has been a critical point for us over the last couple of years to understand how we can improve our product offering and, of course, improve products that help them develop better treatments to be used by patients. You can go to next slide, please. Of course, the last two points in our strategic focus areas are really the people and sustainability. I would say the people are the most important resource that we have at the company. We're very proud and honored to have all of these great colleagues working with us around the world. I say we have the greatest engineers, the greatest scientists, and of course, the greatest salespeople and marketeers that can provide these products and technologies around the world. Something is important is, of course, also bringing new companies on board and making sure that we can integrate these wonderful people, and ensure that they feel part of the great family. One of our great successes has always been the culture, and we continue to ensure that that will be the case for the coming years. Lastly, worth mentioning is, of course, the establishment of a sustainability agenda. We're working now for 2021 and 2022 to establish this first sustainability agenda for the group, establish sustainability targets. The targets that you see below are the UN Sustainable Development Goals that we have selected that are relevant for our specific business. We look forward, of course, to establish a report that we can report back to you in the coming months and quarters. With that, I'd like to thank you so much for your time. I look forward to following the day, and I look forward to your continued confidence in me and the company to grow the greatest bioconvergence company in the world. Thank you, Erik, for explaining in such a passionate way what bioconvergence is all about. We will now focus on the interim report released earlier today, as well as our customer-centric M&A agenda. Here is Group CFO and Co-founder of Cellink, Gusten Danielsson. Thank you for that, Isabelle, and thank you for the introduction. We'll jump straight into the financial targets, as Erik briefly mentioned here during his talk. Our focus is really to grow as rapidly as possible. We established these financial targets just about over a year ago, with the idea of giving our shareholders in the market a understanding of what we're focusing on for the next three years here. We have another one and a half years before these targets will be updated. What we say is that we want to grow with at least 35% organically year-on-year. Really here, the way to look at this and the balance is that we want to grow as fast as possible, preferably a lot faster than 35% year-on-year. We want to do this while maintaining a positive EBITDA margin. Really what you will see and continue to see our focus being is trying to maximize that growth organically. We will continue to grow through acquisitions on top of that, but really balance this with not losing money on a yearly basis, on EBITDA level. Looking at the outcome for 2020, we grew faster than the target and we just achieved the EBITDA target, which is exactly what we were planning on and trying to achieve. This is something that will be our focus for the next year here as well. With that, you have the little bit better understanding on where our focus lies. Go to next slide. During Q1, we saw a continued strong underlying demand for all our products across the portfolio. We saw that demand are continuing to pick up for products all across the two business areas and segments we're reporting in. We see underlying organic growth or growth in all these segments. In the quarter, we saw net sales amounted to about SEK 129.5 million, which corresponds to growth of about 241%. Out of that, about 62% was organic growth. We closed the quarter this time with a slightly, or significantly higher backlog than we've had previously. Usually, our orders in Laboratory Solutions are coming in quite late in the quarter, and what we see there is that when these orders come in late in the quarter, sometimes you can get a little bit of a bottleneck in our supply chain, being able to get everything out of the door. In this case, we saw that we weren't able to get everything out of the door, which is typically the case Laboratory Solutions. if you're looking in Industrial Solutions, we have a lot longer lead times with big customer projects where we make specialized production lines for these customers. Here we can see lead times up to 12 months on these systems. What this means is that we have a quite good outlook on how this will perform over the next 12 months and so on. We also have then a quite significant backlog Industrial Solutions that we work to deliver. The sales pipeline or the sales in the quarter doesn't necessarily correspond to the order intake, as we see more in Laboratory Solutions. in the quarter, we see that compared with, for instance, Q5, our revenue is quite a bit lower than in Q5. One of the main reasons here is, of course, that Q5, which was a special quarter, extended, it was four months rather than three months. This, of course, is part of the answer. The other part is the seasonality of our business, especially looking into Industrial Solutions segment of our business, where we see a very strong seasonal effect, where the second half here, and especially the last quarter of the year, is a lot stronger than the first half year. This is really what you see here in net sales, especially on the non-organic side, compared with Q5. If going to the profitability of the business, we saw the EBITDA amounted to about SEK 34.9 million, corresponding to about negative 26.9%. This operating profit was affected by a couple of factors. One of the biggest one was, of course, the active M&A agenda we saw during Q1, where we acquired Ginolis as well as MatTek. You would also see that our acquisition costs are slightly higher than normal for this transaction. The main reason here is that Ginolis is a Finnish company and it generates a transaction tax that are typical for Finnish transactions. Basically here, about half of these GBP 20.5 million are a direct effect on this transaction tax rather than M&A or transaction costs that we usually have in these processes. I think a more typical way of looking at transaction costs is about SEK 5 million for these average-looking or average-sized transactions that we are pursuing or doing at this stage. The other aspects of the profitability that I'll just address quickly as well is when we have significantly higher volumes in the second half of the year, especially in Industrial Solutions segment, of course, this renders a higher profitability in that end of the year. This is really what we see during the Q1, that the somewhat weaker or the clearly weaker beginning of the year shows lower profitability. This is according to our plans. This is what we were expecting. We do see that with volume is really where our profitability comes, and this is built into the business model with a very scalable business with high gross margins in the products and somewhat higher fixed costs in relation to the business. This bridges us quite good into looking at the gross margin of our business. In the Q1, we saw quite significant improvement of gross margins. I'll go in a little bit more to the details over the next couple of slides here, as well as how we'll look at the services and consumables, what is driving this improvement in gross margins. We can go to the next slide. Looking at this quarter, we're continuing to grow strongly organically, about 62% organically during the year. We also add revenue through these value-adding M&A activities that we've done, especially in the end of last year with Cytena and creating Industrial Solutions segment. We also see during the quarter that we add Ginolis, which is included one month of this quarter. Meanwhile, MatTek is not included in our P&L at all during the quarter, only our outcome balances from the quarter. Including Ginolis and MatTek for the full quarter would have increased our net sales with approximately SEK 58 million. Looking at these two businesses a little bit more closer, we see that the MatTek is a very stable business in terms of seasonality. We see a more even revenue over the year, which corresponds a little bit more with what we see in Laboratory Solutions. MatTek is also part of the bioprinting application areas and in Laboratory Solutions segment. Meanwhile, Ginolis, which is included in Industrial Solutions segment, has more seasonality to it and also similar to what we see in Cytena, where the second half of the year typically is stronger and where we have longer lead time for the products. Meanwhile, MatTek generally have a few days to get these products out, as it's more of a consumable that they are selling. With that, we can go to the next slide. Before just addressing this gross profit, what we see then on the LTM basis is that we reached about SEK 457 million in revenues on the last 12 months here. Breaking down the gross margin development here, we see that for the past two quarters here, we've changed the trend of our gross margin development and improved this quite significantly over the past two quarters. There's a couple of underlying reasons to this, where the main ones are the product mix, where we see that we're selling higher ticket items in relation to our total sales, meaning that we have a few products out there that are on average higher price with better margins than some of our lower priced products. We also see that our pricing power has increased over the past half year or so, where we see that some of our most sold products, such as the BIO X, which is somewhat of a leading star in the group, of course, in terms of sales and number of units. We see that we have better pricing position there, where we're selling them for higher average price. We also see that we're including more and more long-term consumable and service deals with these packages. These things have a long-term positive impact on our gross margin. What we also see is that the development in the currency market affects our gross margin quite significantly from quarter to quarter. During last year, you could see this, especially where we had a higher gross margin in the beginning of the year with a stronger U.S. dollar, stronger euro versus Swedish Krona. Meanwhile, later in the year, as the Swedish Krona strengthened to the U.S. dollar and euro, we saw a decrease in gross margin. One of the reasons we see this is, of course, that we price all our products in U.S. dollars and euros, therefore, this drives, of course, the total profitability of these products in relation to the cost base. The other part here is we have a quite significant inventory, of course, which has been increasing quite significantly during the quarter. The reason for this is the build-up and being able to respond to the increasing demand that we're seeing. What this also generates is that when we revalue the inventory to the current market price, we see that this has a positive impact on our gross margin, which is positive margin contribution in the quarter. However, overall, we do see a positive trend for our gross margin due to the product mix. This will continue to fluctuate up and down with currencies, but underlying, we are making more per product, and we see that the product mix is helping here. This is the reason why we have over 81% gross margin in Laboratory Solutions and over 74% gross margin Industrial Solutions, where we also see similar trends to Laboratory Solutions segment. We're good to go to the next slide. Something that I've touched upon a little bit is the product mix and what we're actually selling. One thing that we're selling more of, which a large reason for this is due to Scienion's contribution to the group, which is a more service revenue-heavy business than the Laboratory Solutions is. What this has done is driving the part of our revenue stemming from services quite a lot from where we saw it over a year ago. We also see this across the product portfolio where we sell more services with our products. We see that products as being placed for a year, they're coming back, getting more and more warranties, and this is something that we can continue becoming better at. A large portion also, this is where we will get and see our profitability in the future coming from, where we have a higher portion of service revenue coming from our products that are placed in the field. They're more efficient service business as the volumes increases, this is something we have one of our focus areas actually for 2021 in. What we see now is that the consumable sales in relation to our total sales has also increased during the start of the year here. We still see this hampered by the pandemic, where in particular in Europe and Asia, we see very low usage on a lot of systems, meaning that we don't sell as much consumables as we'd like to. We see similar things in the U.S., but they are somewhat ahead, where we see more orders coming in. We are also seeing higher order intake of these consumables in relation to when they call off these orders. This is, of course, that they have plans of starting the products, but they get delayed due to pandemic reasons and so on. We're very pleased to see increased service revenue, increased consumable revenue, both especially in the absolute terms, but also in relative terms to our business. Next slide, please. What we see during the quarter is that our revenue growth comes a lot from the North American markets, as we're seeing over the past couple of quarters. We had a 92% organic growth in North American market year-over-year. That corresponds to about 43% of our total sales in the Q1. Meanwhile, in Europe and Asia, we see somewhat of a lagging effect where the pandemic has, especially in Europe, hampered a lot of our activities and a lot of our customers' activities in particular. Next slide. During the quarter, we raised capital. We raised about SEK 3 billion of capital on the 12th of March. We did this through a convertible issue as well as an issue of selling B shares. The reasoning behind this was that we wanted to raise as much capital as we need from the plans we have moving forward, meanwhile, not causing too much of a dilution for our current shareholders. We saw it as a great opportunity to tap both the debt-linked instrumentation such as the convertible bond as a direct share issue, as we know there was a great demand for investing into our business. The convertible issue, what this helps us with is decreasing dilution in relation to direct share issues. We have about a 4.8% dilution if these are fully converted, compared with about a 7% dilution for the directed share issue for the same amount of money that we're raising. However, of course, this runs with interest. We have a coupon about 2.9%, stayed on the same annual basis. The conversion price was about 42.5% above the issue price, which corresponds to SEK 598.50. The last thing I want to address here is in conjunction with the convertible issue, what you typically do is that you offer a delta placing, which means that the convertible investors have the opportunity to, through the banks, in conjunction with the share issue, short the Cellink share. We place about a million shares, helping them to short the Cellink shares. The reason for this is that some of the convertible owners want to have the opportunity of being long the convert and then hedge their market risk in the Cellink share. These investors, who are typical hedge funds and so on, have a typically market neutral, slightly positive exposure to the Cellink in total, but they will show up as if they've shorted the Cellink share in the market. We can go to the next slide. I'll mention our M&A agenda briefly here. As most of you know, we are very customer-centric, focused on our M&A agenda. This is what drives the different initiatives we take in the group. We look at the needs of our customers, we try to address them. If we can't be the fastest or the best there, we will go out and pursue acquisitions, and this is something we will continue doing moving forward. I'll show a little bit on what we've done on the next slide. Looking at the five transactions we've done now over the past basically 30 months or so that we've started our M&A agenda, we have acquired five companies on an average somewhere around four times sales multiple. The multiple we're buying on isn't as important for us as what we see, what we can achieve over the next few years post-transaction. We are very long-term on these. We look at about the five years basis on what we see these businesses would have been traded on in our hands and so on. What we've seen is the Dispendix that we hold, have owned for just about two years, has gone through an 11 times sales multiple to sub one million, sub one x sales multiple. This trend we've seen all across the acquisitions we've done with Cytena, have almost half their sales multiple since we acquired them. Same thing, we're decreasing with Scienion. We hope to see the same trends with the other acquisitions we perform. The reason behind this is that our focus is cross-commercial synergies, meaning the group and the acquired entities need to be benefited by the transaction. This is our focus moving forward on transactions as well. Next slide, please. With that said, I just want to round off with saying that our focus from a financial perspective here is that we want to continue to deliver on our financial targets, meaning showing a positive EBITDA on a yearly basis, continued organic growth, and growth through acquisitions. Identify these first off commercial synergies in the group and over the long period of time, we of course look at operational efficiencies and synergies that we can realize all across the product portfolio. With that said, I thank you, and I think that it's up for one of my brilliant colleagues in the business areas to follow up. Thank you for the summary of the past quarter from a financial perspective. From figures and numbers to Biosciences, here to present is Business Area Manager, Jonas Schöndube. He's also the co-founder of Cytena. Please go ahead, Jonas. Thank you, Isabelle. Welcome also from my side. For those of you who don't know me, I'm Jonas Schöndube. I studied engineering at ETH Zurich and Stanford. After my PhD, I co-founded Cytena. Now it's Cellink. I lead the business area of bioscience. I'm very thankful for the opportunity today to tell you a little bit about the business area of bioscience. As you see an overview on the slide here, we're mostly active in the markets cell line development, live-cell imaging, single-cell omics, and liquid handling. That is distributed over three companies in the business area. That is Cytena and Dispendix in Germany, and Cytena Bioprocess Solutions in Taiwan. In those market segments, we typically sell to biopharma and biotech companies. We're also proud to name some of the most prestigious research institutions amongst our customers. We have a total addressable market of more than $10 billion annually, with some double-digit growth. We're not alone. There are other companies out there. Companies like Berkeley Lights, Beckman Coulter, Sartorius, Becton Dickinson are our peers. In the whole business area, we have a series of products that I'll speak about in detail in some of the later slides. Generally, we follow the business model of selling instrumentation at an attractive margin and then offering proprietary consumables, reagents, and services to our customers for our continuous recurring revenue streams. We anticipate those recurring revenues to that portion to increase over time. As of today, we're very much in the phase of increasing our global install base with the instrumentation. The market position differs slightly from different market segments. For example, in cell line development, we have some of the earliest products for single-cell cloning in the portfolio. Here we have most of the major pharmaceutical companies as our customers, and we continue to work with them. In other segments, we were challengers in, or very fast-growing challengers of traditional solutions. Now, on the next slide here, I want to talk a little bit about some of the major trends that we see in the industry today. Firstly, biosimilars and biobetters. These are basically generic drugs to biologics. Biopharma drugs or biologic have been around for quite some time. Now there are some blockbusters that come off patent. What happens if they come off patent is that there are multiple companies for each individual drug that try to come up with a biosimilar or biobetter. That in turn means that there's a lot more companies in need of cell line development. That's a phenomenon that we see across the globe, from U.S. to Europe to China. We see that cell line development is really becoming mainstream these days. Secondly, cell and gene therapy, as Dr. Langer has introduced as well in his introductory talk, is a very dynamic market. That is something that we've only tapped into recently, and it's a huge opportunity for us. The cell and gene therapy space or CGT space is becoming more and more mature. It holds the offering for unheard-of therapies, and people in this industry are looking desperately for tools to manufacture their drugs. Thirdly, software and automation. In the past month, we've heavily intensified our activities in software development and automation. The life science industry has always been lagging a little bit behind some of the other industries in automation, but the pandemic seemed to have broken that barrier. People have realized that it is essential to have the ability to run your crucial processes with limited staff. We see a lot of requests from customers for semi or fully automated solutions. Together with our most recent sister companies, Scienion and Ginolis, we're ideally positioned to offer best-in-class solutions here. When it comes to software development, we've built up a very strong core expertise in biophysical image analysis, and we can leverage some of the very exciting and recent advances the field has made in machine learning and artificial intelligence. Lastly, number four, there is single-cell omics and analysis at omics. We see a continuously accelerating trend towards analyzing samples on a single-cell level. Traditionally, people have been looking at, say, a patient sample in bulk. Now more and more researchers want to get single-cell data from these samples because it gives them a myriad of data and allows them to draw better conclusions. We have some really nice tools for these people, especially in sample prep. On this slide here, you see some of the main applications. In general, we have a bunch of products in the offering, and we cater to many different customers in the life science industry. In general, you can summarize our applications areas into biopharma cell line development, where we sell to customers in the biologics, monoclonal antibody, or cell and gene therapy space. Liquid handling, where we offer some unique technology for volume reduction. Live cell imaging, where we offer some great microscopes and analysis software. Single-cell analysis or single-cell omics. In the background of this beautiful slide here, you see some of our beautiful products. We're strong believers that our product design should always reflect the quality and ease of use of our products. In the top left corner here, you see our main product for cell line development, the UP.SIGHT. The UP.SIGHT is part of the workflow that I want to talk in to more detail on the next slide. There are three workflows in total I want to speak today about. First one is cell line development, and cell line development is really a key process in getting a biopharma drug or biologic to the market. Most of the best-selling drugs today are those biopharma drugs, and they are produced in such cell lines. These cell lines have to be derived from a single individual cell in the beginning, as is required by regulatory bodies such as the FDA. Traditionally, cell line development is a very complex and expensive process, as you can see on the top half of this slide here. I'm not going to go into very much detail. We can spend more time on this in the question section later. I want to illustrate how complex this workflow is. This workflow is on the critical path for any such drug to hit the market. That means, on average, any week you save in this process allows you to get your drug earlier on the market. Remember, there are multiple multi-billion dollar biologics on the markets today, and that might only have 10 years or so left on the patent protection when they launch on the market. On the bottom end of this slide, you see our workflow offering, including the UP.SIGHT. The UP.SIGHT is the recently launched product that combines multiple instruments into one, and combined with the C.BIRD system that we offer at Sartorius Bioprocess Solutions, it allows you to save up to 13 weeks in cell line development. Assuming you're a biopharma company and you have a $1 billion annually selling drug out there, or want to get it out on the market, saving 13 weeks, that's roughly a quarter of the year, allows you or gives you the- Jonas, we cannot hear you at the moment. I'm not sure if everybody sees the video now. I can see it here on my end. Okay. I hear that everybody else is seeing the video. If you've seen the video, it shows the UP.SIGHT really nicely in action with our double assurance of clonality, and it shows nicely how it dispenses individual cells into each well of such a micro well plate, how they're used in cell line development. The UP.SIGHT allows you to generate hundreds of such clones per hour and document the clonality of these cell lines for the FDA or other regulatory bodies. Now on the next slide here, you see our beautiful workflow for next-generation sequencing library prep, and that's the go-to method for analyzing genes. There's two ways of implementing this workflow. You can do it for single-cell sequencing, it is also used heavily around the world to ramp up sequencing capabilities for finding COVID variants. In the case of single-cell sequencing, the user starts by sorting single cells with one of our single cell sorters. The full workflow continues with our SEQCUE reagents, the i.DOT for nanoliter dispensing of reagents, and the C.WASH systems for DNA purification before these samples go into the sequencer. The i.DOT product is one of our fastest products, it allows you to really precisely and really fastly dispense very small droplets, nanoliter droplets, in very flexible manner, and is currently rolling over the marketplace. The C.WASH system is also something that we launched recently, late last year, in this setting, it allows you to save up to 3,000 pipette tips per next-generation sequencing library prep. That's a whole bag of plastic tips that, A, doesn't need to be purchased, and B, doesn't need to be thrown into waste. On the next slide, you see our workflow for high content screening with cell-based assays. Every time you start a drug development process, you test your compounds or your candidates for the drugs on cells. To do this in a consistent manner, what you typically do is you grow your cells and you stain them, or you add a certain reagent, and then you need to wash these cells. That is something that you can very fast and consistently do with the C.WASH system, and then take those cells and image them in our CELLCYTE microscope that allows you to image these cells in a time-lapse live- cell imaging mann er in the incubator. The results can then be read out with the CELLCYTE Studio software. Yes, that's the exact same C.WASH instruments that can be used in this application as well. Ease of use is something that is very close to our hearts. On the next slide, you'll see some snapshots from the beautiful CELLCYTE Studio, which is unbelievably easy to use. Here on this video, you see how easy the system is set up. It allows you to see live images and analysis in the same view. You can basically run up to 600 experiments in parallel. It offers three-color fluorescent imaging for very sophisticated studies. We offer an AI-based analysis package that trains on individual customer cells. You can train specific applications for your questions at hand. This AI package will become even more important in the future and more future-loaded. We believe this system is really democratizing some of the science that has been very complex and expensive to do in the past, and we're very excited about selling more of these systems. Looking forward to 2021, and what we're really focusing here in the business area, Biosciences, there are three focus areas. One is growth, then there is applications and workflows, and software development. Regarding growth, we are already today on an exciting growth trajectory, we want to accelerate our growth, especially when it comes to recurring revenue streams such as consumables and reagents. We want to do this whilst showing profitability. We continue with our customer obsession, especially in focus area two, applications and workflows, where we focus on the applications such as cell line development, where we have already most of the big pharma customers as loyal partners. We have single-cell omics, where we're offering a suite of exciting sample prep products, and high-throughput screening or high-content screening, where we offer unique nanoliter dispensing, high-throughput cell washing system, and live-cell imaging microscopes. We want to always go to the customer and offer a broader offering in a workflow. We don't have a full workflow in all of these applications as of today, but we're filling the gaps very rapidly, and we see huge value add by going to a customer and being able to offer an entire workflow end to end. Lastly, we've heavily intensified our recruiting efforts in software development, and we've been able to grow teams here in cell and Biosciences by 50% in this year, only in the first couple of months of this year. We believe there's significant value to be added in our existing hardware just by adding more features in the software. That is meaning systems that are out there with customers already and more systems that we will bring out in the future or sell in the future. Software products will be a main value driver for us in the future. With that being said, thank you very much for your attention and the opportunity to speak here. It's been an honor to present some of the stuff that we do at Cellink, and I'm very much looking forward to the Q&A that we will have later in this session. Thank you very much. Thank you, Jonas, for sharing your insights about Biosciences. We will now have a five-minute break. See you soon. [Break] Welcome back. This time you will meet two members from Team Cellink presenting business area Bioprinting. It's Artur Aira, business area manager, and Cecilia Edebo, managing director for Cellink's Bioprinting business. Over to you, Artur and Cecilia. Thank you very much. Hello and welcome. My name is Artur Aira. I've been in the company for more than three years. First in the board, from 1st of January this year, fully operational. I'm going to take you through the business area Bioprinting that I'm responsible for. 3D printing was the beginning of the Cellink journey and its success. Next slide, please. The business area Bioprinting has now two companies, Cellink Bioprinting and MatTek, which is our latest acquisitions. We are the market leading company in our area, and we offer solutions and services for creating and enabling advanced 3D models for drug screening, regenerative medicine, medical devices, organ and human-on-a-chip applications. As a near-term driver, I can mention that there are around 11,000 academia institutions, which represents a value of around $500 million, and around 4,000 cosmetic operations with a value of $900 million. Cellink currently serves more than 1,000 sites of those. 10% penetration. Cellink has around 1,000 systems in the field. The long-term driver, the pharma and clinical market is around $50 billion big. The 3D printing market is expected to reach $1.4 billion-$4 billion by 2024, with a CAG of 20%-35% annually. Our market segments are mainly research, for example, regenerative medicine, 3D cell culture, drug development, and the clinical and medical, for example, blood vessels, bone, cartilage, skin, pills, tissues, implants, prosthetics, skin applications, microfluidics, et cetera. Our customers are within a wide range of segments, as pharma, cosmetic, and industrial food companies, and also in the medtech industry, in academia and research organizations. To have a sustainable long-term business model, we offer complete solutions with instruments, reagent consumables, and services. Next slide, please. The four major trends that will drive the future of bioprinting are the following. We start with the first one, which is the bioprinting itself and its technology. For user's perspective, for example, there is a need of proof of concept, rapid prototyping. It can be study cells and organoids in 3D complex environments, et cetera. Also maybe to understand how the cells work in these conditions that lead to develop new in vitro models of tissue and organ engineering. In production perspective, this provides, for example, shorter lead times, scalable production, cell culture printed or additive manufacturing. Number two is tissue models. The possibility to increase the accuracy of in vitro models mimicking the human body, which reduces the need of animal models, and this is applicable for drug discovery and toxicology. The third one is the microfluidics. For example, applications within human-on-organ-on-a-chip, human and systemic to get more reliable in vitro models that mimic the human body. It can also be vascularization, vascular regeneration, for example, artificial vessels, neural regeneration, et cetera. Number four is the personalized medicine. From one treatment fits all to personalized medicine and treatments based on individual patient data. Next slide, please. This is our offering. We have the widest and most complete offer in the market with light and laser-based bioprinting. We have a solution-based bioprinting, bioink, so what we call consumables or reagents, and tissues. Of course, we offer services as well. Cecilia will address this more in detail in the coming presentation. When someone says cell culture, most of the time they are talking about two-dimensional or 2D cell culture. This is when cells are cultured in a Petri dish or well plate in one or single layer on a completely flat surface. The problem with this is that humans are not flat. Tissues are three-dimensional objects, and studies have shown that cells that make up these tissues depend on the proper geometry and function. 2D cell culture has been the best model for the cell and molecular biology since the early 1900s. Now with the 3D cell culture techniques, we have adopted those decades of research to develop more accurate models with the right geometries. Today, we can culture cells in 3D, either by using their native ability to self-assemble, the scaffold-free approach, or by providing an extra material that they can attach to and interact with, or a scaffold-based. The 3D bioprinting techniques we have developed are examples of the scaffold-based approach, but we also have products in our portfolio to support the scaffold-free cell culture. These 3D cell models offer researchers a way to get more accurate results that will lead to more effective pharmaceuticals much faster. Eventually, these 3D cell models will become transplantable, and we will have created a new market for 3D printing therapeutics. Next slide, please. As far as scaffold-free approaches are concerned, the most common application are spheroid and organoid development. These are small bunches of cell from a specific tissue that self-assemble into spheres and that mimic the tissue they come from. Researchers have come up with many different ways to create these spheroids, as you can see here. This is especially beneficial for cancer research. For example, if you think about a tumor, in essence, it is all a ball of cells that grows uncontrollably. In 2D, you are not able to mimic the geometry. This often leads to inaccurate results for drug discovery research, which costs pharmaceutical companies both time and money. Creating a tumor model in 3D allows cells to behave as they would in the body, making drug testing more accurate. The same is true for scaffold-based approaches. When cells are mixed with materials that make it easy for them to self-assemble, researchers can create more functional models faster. When these cells, laden materials, are 3D printed into the correct geometry, then researchers can leverage the combined benefits of the biomaterial and the architecture to create a model that more accurately mimics the in vivo environment. Next slide, please. To explain you this picture, if we look at the trajectory of the cell culture development in terms of its physiological relevance, we have traditional 2D cell culture, which has been the workhorse of cell and molecular biology for decades. The scaffold-free models, which offer the benefits of in vivo geometry, and now our scaffold-based bioprinting methods, which offer both enhanced functionality and topological benefits. Our products are designed to support the development of these scaffold-based technologies for our customers. Together, we will move to the next paradigm in biotech and pharmaceutical discovery. Our customers right now are much focused at the beginning of this paradigm shift. The models they develop with our technology are already replacing animal studies. As these models became more complex and clinically relevant, those new ways of creating implantable tissues, and eventually organs, will constitute a new normal in pharmaceutical testing and drug development. Our customers are working in tissue engineering, basic cell biology, drug discovery, and even soft robotics. What they have in common is that their work is unique and recognizable. The value of our bioprinting technology to them lies in the flexibility of our bioprinters to create complex structures at a high throughput, and the ability of our bioinks and biomaterials to offer unparalleled quality and functional relevance. Next, please. Not all researchers are interested in developing the models themselves. For researchers who are more interested solely in drug discovery or toxicology, we have also developed ready-made humanized tissue models that are ready for testing. This technology not only limits the need of animal testing, but also provides a model using human cells. As beneficial as animal testing has been for drug development, now it's time to do better and be more sustainable, and generate results that can be applied directly from the bench to the bedside. Our goal is to provide the technologies that support the development of the right therapy for the right disease and for the right individual. Next slide, please. This goal is even shared with regulatory organizations. As a new mandate from the U.S. House of Representatives has ordered a reduction of animal testing and drug prices in the pharmaceutical industry. The only way to meet this goal is to develop relevant humanized models. Perhaps the representatives are primarily concerned with ethical concerns. We know that this initiative will also foster more effective data generation, increase profit margins and even capital gains, and serve as the foundation for a better way of the pharmaceutical development. Next, please. One of the examples we have among our tissue models is the MelanoDerm model. This is probably the most fascinating model to me. Anyway, this model is ideal for the assessment of the skin lightening agents and formulations. MelanoDerm is used by dermatology scientists worldwide, replacing animal models as well as reducing the time and cost associated with clinical testing by screening compounds and formulations in MatTek's MelanoDerm 3D tissue model. This model contains primary human melanocytes embedded into the epidermis, similar that of in vivo. This model, you can see in the image, when treated with water or untreated over the course of six to 14 days, the model actually pigments in the dish, and so it's really fascinating to watch it happen. Looking at obviously the effects of the toxicity on the skin models from the creams or formulations or raw materials, and we'll also look at the pigmentation or the level of lightening that the active ingredients do cause. Next slide, please. Cecilia, you are welcome to present. Thank you, Artur. My name is Cecilia Edebo. I am Managing Director of the Bioprinting business. As Erik shared with you earlier, Cellink started by creating the world's first universal bioink. In order to democratize the industry, Cellink also developed affordable and user-friendly bioprinters. 3D bioprinting today represents approximately 6% of the 3D printing market, whereof extrusion-based is about one-third and light-based is about 10%-15%. The INKREDIBLE system, which you can see in this picture on the bottom left, was the first extrusion-based printer made at Cellink. Based on customer feedback, the INKREDIBLE was created with a lean, open design, exceptional functionality, and an affordable price. It also comes with our patented clean chamber technology, which uses UV lights to create a clean environment inside the printing chamber. Came the BIO X, which is our flagship bioprinter, as Gusten mentioned earlier. You can see it on top middle. With this instrument, we introduced a truly market-disrupting touchscreen display. It comes with three slots, as you can see, for our patented exchangeable printhead technology, and has temperature control for both the printhead and the print bed. This instrument is two times winner of the Red Dot Award. The BIO X6, which is just below the BIO X in the picture here, offers the same standards of quality and functionality as our flagship BIO X, while also offering an unparalleled flexibility and user experience with six printheads, allowing researchers of advanced applications greater complexity in creating multilateral structures. This system is a winner of both the Gold and the Red Dot Awards. The LUMEN X, which you see on the top right, is a digital light printer. It is actually the first DLP bioprinter in the market. This printer works by projecting light in a specific pattern onto a photosensitive material, one entire layer by layer. When the light is turned on, the material hardens everywhere where the light touches. The places where no light is present stay liquid, which enables development of vascular models. The Holograph X, which is bottom right, is a laser-based bioprinting technology. This system uses a similar mechanism as the LUMEN X, but instead of projecting light on an entire layer at once, this system projects light point by point. In this way, much smaller constructs and much higher resolutions can be achieved, and much faster. The Holograph X can print up to 150,000 points of light per second. Our mission is to secure all types of applications of 3D bioprinting, offering customers complete solutions with high quality instruments and bioinks. This is how we will continue to outperform the market. Please, let's see an example of what we can do. [Presentation] Thank you, Cecilia. Summarizing, focus for 2021. The first one, we will continue with strategic acquisitions and capitalizing on the synergies in the group. We will focus on technologies that will fill the gaps in our product offering, as well to grow our portfolio of reagents and consumables. Number two, we will continue our mission to contribute to decrease the animal testing by providing market-leading solutions. Number three, we will explore the commercialization opportunities in personalized medicine, microfluidics, vascularization, and the regeneration of organs. Thank you very much. Thank you for your presentations. We will stay in the wonderful world of Bioprinting. Product development is the backbone of the Cellink Group. Here to present the BIO MDX series, a major invention, and the first time ever technology is converging from different parts of the group. Dr. Héctor Martínez, CTO and co-founder of Cellink, and once again, Cecilia Edebo, Managing Director for Cellink's Bioprinting business. Please go ahead. Thank you for welcoming me again. Thank you, Isabelle. It's truly an honor for me to present a truly customer engineer technology which will take 3D bioprinting to an industrialized level. As I told earlier, Cellink started by supplying benchtop 3D bioprinters to democratize the industry by making it affordable and user-friendly. We listened to our customers and developed the award-winning Bio X system, as I told you about earlier. This is today the world's most sold 3D bioprinter. We have now listened again. We are now presenting really the next generation of bioprinters based on our customers' feedback. The Bio MDX series is the first of its kind. It is optimized for high throughput biofabrication, combined with high precision dispensing and quality control, as well as a unique modularity of technical combinations. This unique medical device crossover has been enabled by combining technologies from the companies within the group. The BIO MDX technology, as I said, enables both high throughput as well as high precision and quality control. This is truly key for R&D labs and companies engaged in drug development to perform disease modeling, drug efficacy testing, and toxicology testing. T his is enabled through high batch production of smaller constructs or in well plates, followed by analysis. This technology is also key for R&D labs and companies engaged in production of smaller implants, such as cartilage, skin, cornea, tissue patches, et cetera. This technology is also key for companies engaged in cosmetics, as Artur mentioned earlier, but also personal hygiene and wound care development. Our vision with the MDX technology is to enable these companies to fulfill their missions. We at Cellink continue on the journey to create the future of medicine, a future of superior insights and free of animal testing, thanks to more physiological relevant models. We believe this is a true win-win-win. [Presentation] Hi, everyone. My name is Héctor Martínez. I'm CTO and co-founder at Cellink, and the CTO for the Cellink Group. Welcome, everyone, to the world of 3D bioprinting. Thank you, Cecilia, for the wonderful talk. It is my pleasure to introduce you to the latest product development that simply enables cell-friendly, precise, and user-friendly bioprinting at unprecedented speed and high throughput. I'm going to show you a few features why the BIO MDX is the first of its kind. It has been established as the medical device crossover, enabling biomedical researchers to transform their biomedical innovations into medical applications. It's truly opening the future of personalized medicine. How do we at Cellink enable this, you may ask. By converging over 25 years of R&D in a wide range of cell printing technologies, high precision robotics, software development, machine learning, UX design, and most importantly, biology. That's how we enable this. We're also building on the patented clean chamber technology. The BIO MDX offers uncompromised sterility with HEPA filters and UVC germicidal lights. Also, we're offering the largest printing area of any other system in the market, 82 by 36 square centimeters. To put this into perspective, our customers can now print more than 30 large-sized medical devices in one run, compared to one by competitors. Also, if you can go to the next slide. Also, our unique and patented technologies in microliter, nanoliter, and ultra-high picoliter printing resolution, we're enabling unique applications for bioprinting microtissues at single-cell resolution to single-sphere resolution, and all the way to printing microtissues with multiple cell types and more complex vascular features and multi-scale features. The BIO X has up to six printheads and can also be equipped with up to six dispensing channels, allowing our customers to leverage multiple biofabrication modalities in one system. To demonstrate our strong commitment to the Bioprinting community, the BIO MDX users now have access to the unique sciDROP technology through the acquisition of Scienion. This now enables them to place multiple cell types and spheroids in an arrangement which makes more sense from the biology perspective. For example, the sciDROP PICO can be used for patterning cells or biological gradients at the cell level, while the sciDROP NANO can be used for patterning biological gradients directly on the bioprinted filaments. These are really innovative and fascinating technologies. Now today with the BIO MDX, users can appreciate what precise temperature control really means when working with temperature-sensitive materials such as collagen and cells. The BIO MDX can print the widest selection of materials in the market, this is basically due to the dynamic range of temperature control in the printheads, print bed, and printing chamber. We have converged all of these advanced technologies into one product, it's coming from one purpose in mind, where we envision a world where patients and doctors have access to personalized living implants to repair damaged tissues. Next slide, please. Here in this slide, you can see the BIO MDX workflow for batch bioprinting of personalized medical devices. In the first step, you have the researcher mixing the desired human cells with tissue-specific bioinks, initiating the bioprinting protocol. At that point, the automated bioprinting starts. During the bioprinting process, the user can utilize the sciDROP technology to precisely pattern cells in biological gradients, such as growth factors at the micro and macro tissue levels. This is to stimulate the tissue development. At the end of the bioprinting process, the tissue's 3D structure is stabilized by exposing the tissue to light or temperature changes. The BIO MDX is also equipped with computer vision systems to inspect and quality assure these 3D tissues with the help of machine learning algorithms. The researcher then puts the quality assured bioprinted tissues inside an incubator over a period of time for maturation. During the maturation period, the researcher can also do a number of widely available analysis that we also support. These include qPCR, single-cell omics, and high-content live-cell imaging. This is to determine the maturation of the human tissues. What's also amazing about this workflow is that it can also support the drug screening process. Francis Collins, NIH director, said in a TEDMED Talk, "We test drugs on animals, and it's not reliable. Ultimately, the ability to develop and test medicines will be organ on a chip. He said this while describing the challenges with animal models and the new developments in 3D tissue models. This is the market most advanced bioprinting workflow that our customers will leverage to push the limits of science, and we stand behind it. Day after day, our passionate and persistent team empowers biomedical researchers with the tools they need to bioprint human tissues. We find our customers truly inspiring, and we share their vision. This is why when our talented teams make the impossible possible, the result is another award-winning product that customers love. I invite you to follow our journey as we continue to serve the thousands of biomedical researchers which are part of Cellink's Bioprinting community, which is also the largest in the world. As we continue to provide them with the latest bioprinting technologies in the market. Thank you for your time. Thank you for presenting in detail about the BIO MDX series. With our next session, we would like to highlight how we work and interact with our customers and collaborators. This will be hosted by Itedale Namro Redwan, CSO for Cellink Bioprinting, and Mariana Andrade, Head of Customer Success. Hello, and welcome everyone to Cellink's First Capital Markets Day. We're of course, very excited to be part of it. Of course, very honored to have gotten the responsibility to present our customer session today as well. Our first customer today is A.J. Mellott from Ronawk. He is the CEO, President, and Co-founder. Thank you for joining us today, A.J. Could you please just start telling us a little bit about how did you get to know Cellink? Sure. Thank you for the invitation today. I'm excited to be here. Our journey with Cellink started several years ago when Cellink was actually just starting, and we were looking at 3D printers on the market. At that point in time, Cellink was offering the INKREDIBLE. As I got to know the founders and the team, what really impressed me, and why I ultimately decided to purchase an INKREDIBLE, had to do with the customer support. From there, over the years, we've had a wonderful relationship that has just evolved. Great. What products have you bought so far? So far, since Ronawk has spun out from our former university, we have acquired the BIO X, multiple LUMEN X's, and also, forgive me, the Cyto microscope. Yes. The CELLCYTE. Yes. How do you use these products in your business today? Today, we actually use both the LUMEN X and the BIO X in tandem for different things. The BIO X is our main workhorse bioprinter for prototyping new designs and new hydrogel scaffolds. We use the LUMEN X actually for production, and we make our primary product using the LUMEN X, and then we use the CELLCYTE to actually do a lot of our QC work and looking at how cells perform in our hydrogel scaffolds. Nice. That's great to hear. Thank you for sharing your story with us today, A.J. We really appreciate your time. My pleasure. Thank you. Our next collaborator is Dr. Richard Hanna. He's Associate Principal Scientist in the Respiratory and Immunology group at AstraZeneca. Hey, Itedale. Hey, good morning, Richard. Morning. What a pleasure to have you part of this discussion here with us today. Can you tell us what the partnership between us is about? I think we've been partners for two or three years, maybe three years now. We have a full-time Cellink person on site to help us implement some of the technology. We have three or four of the bioprinters at our location. We have the BIO X, the LUMEN X, the new imaging machine, the CELLCYTE X. I think it's helping us develop models for drug discovery. We're trying to do fluidic devices, incorporate the new technology into our work stream for drug discovery. Thank you. Thanks for sharing. What questions are you trying to solve with our technology? Yeah, we're trying to develop new models. I guess right now, we're trying to get ex vivo, better than 2D culture. We're trying to make these fluidic models of different tissues, things like gut, liver, lung modeling. People are interested in some implantable devices and these kind of things. There's a lot of different things going on. I think it's just more getting the technology to develop. I think it's new technology, and we got to get it into the pipeline. It takes a little bit of nudging to get these things up and going. I think it's been very helpful with Cellink to have these technologies and the assistance in developing these technologies. I'm very glad to hear that. We know that you have a rock star helping you out in AstraZeneca, Gaithersburg. Yeah. How is it to work with the Cellink team when they are on site and helping you really solving. Yeah -the science stuff? I mean, super helpful. I mean, Chris is on site. Anything we think, anything from designing a new model, he helps. He can look in the background and if he doesn't have an idea, you can contact the Cellink team and all the knowledge that you guys have from the bioprinting. You can share anything, non-public kind of models and different aspects of gel design and incorporating cells into these models. It's been very helpful in developing this technology a lot faster than it would be on our own. I think it's a great interaction. I have a post-doc working with Chris, and then I think different groups have different ideas, and I think it's good to get these ideas developed and incorporate this stuff into the pipeline. Thank you very much. Of course, we're looking forward to a continued amazing collaboration with you, your team, and everyone else at AstraZeneca, Gaithersburg. Last but not least, we have Dr. Bernard Tsui. He's Principal Scientist at the Pre-clinical Development Department with expertise within quantitative bioanalysis and laboratory automation at Merck. I would like to start by asking you a little bit about how long you have worked with Cellink, and how has your relationship evolved over time? We're relatively new customers to Cellink. We just purchased a few i.DOTs this past year. That said, we've always had an eye on your products for specifically i.DOT for years. We were always interested in contactless dispensing capability, the timing at the time, a few years back, was just not right. We were heavily invested on existing workflows using the traditional air displacement pipetting liquid handlers. Now there's an increasing interest in miniaturizing our assays, having the capabilities to do design of experiment, and the mainstream availability of machine learning and data science capabilities is making tools like the i.DOT increasingly more important. Nice. Can you describe to us a little bit of your business, your current challenges, and also what is your mission? Part of my duties is to improve the overall efficiency for quantitative analytical workflows from discovery to the clinical groups. We're always looking for faster, more efficient, more cost-effective ways of doing our work. Traditional automation systems using air displacement tend to be slower. They tend to use larger volumes of reagent, which tends to be costly. In addition, programming the larger liquid handlers can be quite complex, and the i.DOT provides a platform that can do a lot of those features in a more compact, user-friendly platform. How did you work nowadays with the Cellink products? Well, we acquired a few i.DOT products, and we're closely evaluating them for support for discovery assays, PK/PD, quantitative biologics, and vaccine workflows, and PCR. We're hoping that a lot of functions that traditionally perform on air displacement pipettes systems can be transferred to your platform. We're heavily exploring that opportunity. Great. A lot of good things happening. Thank you for your participation today, Dr. Bernard. My pleasure. Well, I'm glad to have had the chance to share these customer stories with you all today. Thank you everyone who's listening for being part of this event. We're hoping that you enjoyed it as much as we have. If you're interested in finding out more about all the amazing work that our customers are doing, please do visit our customer spotlight page. Enjoy the rest of the event and of course, the rest of the day. Thank you, Team Cellink, and an extra warm thank you to A.J. Mellott, Richard Hanna, and Bernard Tsui. We will now take a break. See you in five minutes. [Break] Welcome back. In September 2020, Cellink acquired Scienion and Business Area Industrial Solution was born. Holger Eickhoff, Business Area Manager and founder of Scienion, will now present Industrial Solutions. Hello, and welcome to Industrial Solutions section of the Digital Markets Day. It's a pleasure to present this for you here. We have been part of the Cellink family now for a little bit more than half a year, and we have had a very warm welcome. It has been a pleasure to work with the team in Gothenburg, and it's really nice to see all the synergies that we go for together. Just as a remark, because Professor Langer mentioned the nanotechnologies and their great future, I hope that after today's presentation you will appreciate what Scienion and Ginolis and Cellenion can do in 1,000 folds smaller format, because we deal with picoliter technologies or picoliters. The business area Industrial Solutions actually consists of three companies, where we have Scienion as a precision dispensing company, Cellenion, originally a spin-off from Scienion as a single-cell, precision handling company, and Ginolis, that has been part of our business area now for the last two and a half months, which are absolute experts in automation, and we have great synergies with them, especially in the diagnostics and biosensors market segment. That's where we are very active in and where we share the same customer base. All companies in Industrial Solutions business area, we enable our customers to automate processes with picoliter and nanoliter liquid handling. With this kind of very small amounts of precious, typically very precious reagents, we enable the generation of very affordable tests because the cost of goods go down significantly. In our sales and business model, we sell instruments, consumables, services, in contrast to all what is the main competition, we also sell contract manufacturing, meaning that a customer that approaches us can opt for either an instrument or a service, which none of the competitors, according to our knowledge, does. The total addressable market for diagnostics and biosensors is about SEK 40 billion. It's estimated to be SEK 40 billion. Single-cell analysis, currently about SEK 2 billion. Both are growing at a two-digit rate, we are trying to address this market with our product offering, where I've listed the names here. sciFLEXARRAYER S from Scienion, LFDA, Cecilia, Ginger software are from Ginolis. cellenONE Fluorescence, the cellenCHIP and proteoCHIP are products from Cellenion. We as Scienion also sell readers and contract manufacturing. The customer base is mainly diagnostic companies, also bioprocessing and pharma companies, research organization, and academic institutes. As a fundamental business concept, we try to accompany our customers from very early R&D to full-scale manufacturing. By doing so, we have gotten a quite good market position in the diagnostic space, where we, especially on the pandemic times, a lot of the diagnostic players are Scienion and Ginolis customers or Cellenion customers now. We assume we are the precision dispensing market leader, we are very fast mover in the single-cell genomics and proteomics field, also we entertain a lot of key accounts in drug delivery. What we see as major market trends right now and the market drivers are molecular diagnostics and wearables. Without going into detail with that, we have a lot of customers in the human diagnostics space, but DNA is DNA, and we also really empower systems in veterinary diagnostics, food and feed, and also in chronic diseases like cancer or rheumatoid arthritis. We are very active in precision medicine, where we provide the ultimate precision at a single-cell level to our customers, especially also for liquid biopsy markets because we have a sampling tool, which I will introduce later for this. We have been very active in COVID testing. There is probably more than 20 companies that utilize our technologies for nucleic acid testing and antigen testing, PCR, LAMP, whatever. We are in there. We propel early technologies forward. What we have seen in the pandemic is also that there is a lot of companies actually have moved back from low-cost labor countries back to their home bases because with human labor, a lot of mistakes got introduced into the products, and that can be get rid of with kind of automation and appropriate software, which we have, and this kind of helps us moving forward. Some of the products utilizing our technology are shown on the next slide, where from left to right, you see probably what many people have seen over the past year or so, a COVID lateral flow test. We are also very, very active in all kinds of sensors and wearable business, so it starts typically with some big applications like diabetes and continuous glucose monitoring, but it's not limited to that. We are active in programs with sweat sensors or breathalyzers. More to the right, you will find in the center of the page down a kind of medical device, which is a drug delivery device, from a company called Tandem Diabetes Care. It's an insulin pump called t:slim that's completely built utilizing Cellink technologies, and we have also other drug delivery systems, which are shown in the little bit greenish colors. These are microneedles that are 200 micron high and that were originally developed as vaccination tools for pain-free delivery of a vaccine originally for flu. Maybe this was going to come back at a later stage. There is other applications for that in the cosmetics area as well. We also offer single-cell omics solutions which have entered the scientific community and which is actually resulting in great papers from a number of groups throughout the planet. How the technology works in detail is shown on the next slide. We are a precision dispensing part of the business, and we combine the dosing of nanoliter amounts and of picoliter amounts of both dead matter solutions containing DNA proteins, antibodies, and the like, and living matter. The color code for that is everything that we dose in dead is labeled in green, and everything living is labeled in pink. We call those products sciFLEXARRAYERs, it's the left-hand side, and on the right-hand side, that's the cellenONE technology that is utilized to dose single cells and all, but also other particles like spheroids and organoids. You might easily imagine with what Artur and Jonas have mentioned before, what that means in an automated process. Which are the processes that we are after, which is scaling those technologies that are from an R&D perspective, as mentioned before. The next slide shows you how those look like. We have a flagship product called the sciFLEXARRAYER S100, which is a fully scalable, automated, and conveyor belt-based system for precision dispensing onto any kind of substrate into any kind of cartridge. What we have done to all those lines is that we have actually added a lot of quality control so that we know exactly now, in contrast to many others in the field, what goes on, where we have deposited something, what volumes were there. Again, since we are delivering very, very small volumes, which can be as low as 10 picoliters, we are typically very, very sustainable, resource friendly, and allow a kind of a very, very inexpensive diagnostic product in the end. One of the products that was really asked for in the last 12 months is shown on the next slide, which is a product for lateral flow device manufacturing. This will be delivered over the course of the next years for cartridge making of all the rapid tests that many of us have seen and that we have probably used and the possibility that you might have used a test that has been produced utilizing Cellink technology for COVID testing is relatively high. We have those LFDA makers, which are actually the cartridge makers for any lateral flow test that can be as quick as 80 parts per minute per line. They have a standard footprint, but still very flexible in terms of what cartridge has to come in and get out. There is all the kind of intelligence software and QC in it. What is very important for us is that this is a modular technology because with the modular technology, we can add functionality to the systems, which enables us to meet all the upcoming requirements for future products. A more integrated line is shown on the next slide, which is a complete medical device manufacturing line that is utilized for making medical product. In order to get this product, there's a lot of R&D results that have to be implemented into those modular systems. As you can see in detail, it involves surface treatment, so with kind of, for example, plasma spray coating, UV curing, dispensing, all the testing, marking for good parts or bad parts, cutting everything, singularizing stuff, drying, bonding, ultrasonic welding, assembling everything together and package everything. Really have an end-to-end solution for our customer. Since we are not only engineers but also biologists in the company, we try to add more biology tools or systems, and this biology is shown on the next slide, which is the cellenONE technology, which is a technology that allows to dose single cells living. We have this outstanding data for recovery of all kinds of different cells. Beside all the applications that Jonas was mentioning earlier, in cell line development and all the automation that comes along with this, we are very much after the markets in liquid biopsy, also getting a more consumable business with that tool. For this, we will enter and have entered the single-cell omics field and a very central tool to address those is shown in the next slide, which is the cellenCHIP. Isabelle, if you could go one slide ahead. Here we see the cellenCHIP, which is a platform where we have nanovessels in a plastic shape and where we can dose single cells and all reagents required to do either a library for single-cell sequencing or a proteomics workflow, which is a slightly different setup geometrically. Fundamentally, what those tools offer is that we can actually image a cell and we can attach and sequence all a proteomics, a single-cell proteomics signature to all the cells that we have imaged before. We have released those technologies to key opinion leaders where in the single-cell genomics world, we have entered some very high-ranking journals with groups from UCSF and UBC and also groups in Lyon. We have just done a single-cell proteomics seminar that had about 450 participants. Seems that we are at the forefront of science there. That's what we are very keen on and very proud of, that we can offer these cutting-edge science tools. What this means for the bioconvergence concept is shown on the next slide. Bioconvergence has many parts in it, and one central part is that the life expectancy is going up and because of that and all the chronic diseases, for example, cancer, heart disease, or diabetes, the health-related expenditure is going to go dramatically up over the next years. About 50% of those are kind of chronic diseases or to a large extent, it's chronic diseases that play a crucial role. Within Industrial Solutions area of Cellink, we can provide tools actually to monitor the disease and also drug delivery tools to treat the diseases. This is also true for very early and efficient testing and intervention. On the slides there with the integrated devices is in all this disposable film, where we could print onto all kind of drugs according to the different states of an individual, be male, female, thin, not so thin, and so on and so forth. We are working on combining semiconductor biosensors with optical sensing method and heat maps where you get the positive result. We are always in what helps where it is required to get very affordable diagnostics in a lot of market segments. As I've said, this is not only important for the point of care or lateral flow test, what most people have in mind, that's also true for the single-cell business, which is on the next slide, where we all are part of the genomics revolution. There's more and more data coming, and it needs to be connected with IT systems. We have entered that stage, and actually, we have, I must say, we collect data in the genomics, and our customers do, they collect data in the genomic space, but also we enable our customers to do this in the proteomics world. Of course, there's gene therapy and CRISPR-Cas methods that all require cell handling and so on and so forth. We have the tools to absolutely automate and industrialize this with affordable prices, and that will keep us going, developing new methods and tools. That brings me to my last slide, which will show the focus of 2021. We are currently working on getting a combined offering together to our joint customer group. That's the most low-hanging fruit to get end-to-end complete solution for medical device diagnostics and drug delivery. We have launched some part of the cellenCHIP consumables. This will keep us busy for the remaining years and will result in a good consumable business. We'll be focusing on a unique cloud and bioinformatics offering for especially the single-cell business, not to say that we need to go into a higher ISO certification. Geographically, we want to expand to Asia. Having that said, I would like to thank you for your attention. I'm happy to answer any questions later. Thank you, Holger, for presenting why diagnostics plays such an important role in society. We have reached the final session for today, the Q&A, which will now be hosted by Ulrik Trättner, Equity Research from Carnegie. Thank you very much, Isabelle. Hopefully everyone will hear me all right. As you mentioned, my name is Ulrik Trättner, Research Analyst at Carnegie Investment Bank, covering, among others, Cellink, and I'm very happy here to be part of this first Capital Markets Day that Cellink is hosting. You are able to ask questions through the portal, and I will try to forward as many of those as possible. I'll start off with the ones I've received. I think this one relates to Dr. Robert Langer's introductional speak on Cellink and the collaboration, and as mentioned through that presentation, is Cellink's potential exposure to nanotechnology and if that is an area for further expansion or focus? I think that's a great first question, and I can take the first dive at it. Nanotechnology is an extremely exciting area, but it's also a very broad one. It's in relations to material science. It's in relations to creating better environments for cells. It's in relation to drug delivery, drug discovery. It's covering so many different areas, which makes nanotechnology really such a broad subject. I think from our perspective, nanotechnology is something that we work with, and we provide technologies that can enable faster development within that area. By no means would I say that we are targeting nanotechnology as one of our main application areas for the futures to come. I think one important point to mention, if you just listened to Holger's fantastic presentation Industrial Solutions and biosensors and a lot of the diagnostics world, nanotechnology is going to play an important role for those types of industries as well. Again, I think it's present in a lot of things that we do. Great. Thank you very much. The second question is as well from Rickard Anderkrans from ABG. I think this is perhaps directed to you, Gusten, or a combination of Erik and Gusten, it's related to which areas or capabilities are prioritized in the near-term M&A agenda. If you look a little bit on the focus areas of the different business areas, these are the areas where we want to expand as much as possible and continue to cater for our customers. Looking at it from an M&A perspective, where we have weaknesses or lack technologies in these areas are areas where we're looking into technologies. It could be anything from what Holger mentioned in bioinformatics to technologies helping us with analysis within these areas. I'd say that analysis is something we're looking heavily into right now. Great. Thank you very much. Since we're on the topic of M&A, and we have both Dr. Schöndube and Dr. Eickhoff with us today, newly integrated companies, it would be interesting perhaps if you, Jonas, that has been part of Cellink for the longest of these two companies, could just talk to us about how you have changed your operation since you've been integrated into Cellink. What is different, what is similar, and what's your experience of being integrated into Cellink? That is a very good question. Thanks, Ulrik. I've been part of the Cellink Group now for around about four and a half years, slightly more than that. We were on a very good trajectory as Scienion before, being part and becoming part of Cellink has really propelled a lot of our activities forward. It was very synergistic to merge the commercial entities, it has allowed us from being a small German startup before to have really global reach and be able to cater to more customers around the globe. That has really had a very, very positive impact on the company in total. We have used some of those opportunities to invest and be able to launch a lot more products in the past. When Cytena joined Cellink, we were a one-product company, we have expanded this to now three product lines. That has been very, very cool for me as a person, but also for the entire team here to see and to grow with these opportunities within the Cellink Group. We've been able to structure the group into business areas a couple of months or half a year ago or so, and that has allowed us to work very, very closely with some of our sister companies, where we have very interesting cross-selling synergies. We sell a lot of Cytena products with, for example, Dispendix products, the i.DOT, and that's something that is really nice for the customers because they can go to us and get a full package. We can offer attractive pricing, we can offer workflows, and that's certainly a value add. For us, it has been very exciting journey. Great, thank you. Perhaps we could switch to Dr. Eickhoff. It's been not that long since you've been integrated, but perhaps your initial thoughts on the integration process and being part of Cellink. Obviously, the recent integration of Ginolis as well, and your impression on how it's been on integrating these into the group as a total. It has been an absolutely fantastic journey after the acquisition. The acquisition, actually, it was like releasing a break from our company, Scienion, before the acquisition and after, because now under the Cellink umbrella, we can focus very much on our operative business. We were after acquisitions for many years that we couldn't do, which we have actually executed now together with the team at Cellink. The integration was difficult because we had COVID and we still have COVID. Despite the pandemic being around, we actually, I think we did do a very good job together, where we kind of figured out what the best way of working together is. We have great synergies, for example, in marketing. We learn from each other when it comes to automation. It's a great exchange with the people in Freiburg and Stuttgart. I can't complain at all, and I would say that we have. Actually, Scienion, as a company, is 20 years old, or young, depends on how you look at it. We are innovative and have met a very innovative team, and I think we share the same values at Scienion. We were always very passionate about things, which is the same at Cellink. I think we are now a much quicker organizations than we have been before, where we adopted from the Cellink younger company speed concept. Great. Thank you both, Dr. Eickhoff and Dr. Schöndube. If we could perhaps go back to the fundamentals of Cellenion, and perhaps best to address this question would be Héctor Martínez. Just to get a better understanding on a company like Cellink has been able to develop, produce, and launch competitive products at a competitive price compared to what's out there in the markets today. Just walk us through how you differentiate yourself to the competitors and how you've been able to build a market position in the certain areas that you have today. That would be part one of the question, and the second would be looking at the integration between the acquisition, looking at IP transfer, what should we expect in the future between these companies? There seems to be quite a lot of technical overlaps and synergies as well on the technological side. What should we just look out for? Thank you very much, Ulrik, for the great questions. First of all, looking at the product development and how we even consider this new technology, new products. As Erik already mentioned, it really starts with the customer in the center and talking to the customer really, going a few levels deep into their pain points and analyzing what are they trying to achieve. That's the big question that we need to continuously ask, what is their ultimate goal? From there, once we get to the bottom of their pain points and what is it that they really want to achieve, how do we position ourselves? How do we position our products, or how do we align our product development teams to be able to address those problems? For example, when we look at technologies that have been out there for many, many years. Right now the customer needs to do their own research, looking at, let's say they're in a cell line development workflow, or if they're in a drug screening needs. They need to take each of those technologies, determine what is the best technology for each part of the process, and then try to do the integration themselves. The way we see it is that, okay, let's develop the best technologies as an integrated platform so that the customer can get an end-to-end solution. That's exactly how we work across the group as well. Everyone has their business, prioritizing, of course, the customers, prioritizing the products. At the same time, we have a platform where we can collaborate and bring these amazing workflows that fulfill very specific needs for our customers and that generate a lot of value for our customers. Great. On the second part of the question regarding IP, we have an aggressive patent growth strategy where we are working within the companies. We have our targets, of course, for filing patents. There's a lot of innovation in the field, we need to capture that. We need to protect our ideas. We have a target which is aggressive for each company, for each business area, and for the group to be able, or to make sure that we capture all of those innovations happening when we talk to the customer, when we go back and do our homework, spending millions of dollars in these developments, in capturing these nuggets each quarter. When it comes to integrating this IP, of course, we have a specialized IP within each company, but also we have our CTOs, CSOs working together to make sure that we also catch the nuggets which are in between the business areas. We have the process in place and the platforms in place to be able to come together and capture those workflows that are solving very unique or providing very unique solutions to our customers. Great. Thank you very much, Héctor. If we could move back perhaps to Jonas and Biosciences, and you mentioned something quite interesting. It's related to gene therapy and your ability to add benefits to that specific industry. Could you just walk us through how your product would contribute into gene therapy development? A very good question as well. Cell and gene therapy is obviously a fairly new field, and there's a lot of companies popping up and working on therapies in this space. A lot of the workflows and processes are not standardized yet, as we see it in other industries like biopharma or monoclonal antibody manufacturing. There's a lot of work going on between us as vendors for certain tools and the biotech and biopharma companies in trying to come up with better and better processes. Currently already now, some of our existing products are used to handle cells and to do live cell imaging on those cells that people are editing. There's a lot of stem cell work there. We're continuously working with these customers to improve the processes specifically for this upcoming and very innovative industry. We anticipate that a lot of R&D efforts in the coming years will be tailored towards these applications as that is a very attractive growth market. Great. Thank you very much. I think we will have time for one last question, if we can have a short answer, and this would be then addressed to Artur and Cecilia within the field of Bioprinting. Just your high-level thoughts on what is the current limitation in the industry of implementing 3D dimensional, both tissue and cell line development models currently, and what do you believe needs to be brought to the market in order for this to get higher adoption? Would you like to take it, Cecilia? You can start, and I can continue and add in- Okay -probably what I give as a perspective. Yes, of course. I think something that it's very important and also a prerequisite is that even if we are enabling the market with solutions that are a foundation for the prerequisites that they will use to be able to develop new methods and also to replace the traditional cell culture, and as I mentioned in my presentation. I think to be able to jump into the next level, of course, is to apply these new technologies into practical solutions that you are using in your lab. This is, of course, going quite fast, but it's something that we are driving together with our customers. In the end, it's the customers that needs to drive these applications. We are just creating the prerequisites to do that. No, that is very true, Artur. I think what we are still at a very early infancy stage. We are the market leaders, obviously. We have placed some 1,000 instruments out there. As Artur mentioned earlier, we have about 11,000 just academia labs. We haven't even touched into the more industrial level bioprinting levels. This market is still at the very early stage. The different technologies that I mentioned before are, extrusion being the dominant one today, but also light-based and laser-based. Those are very good at complementing each other and achieving all these different workflows and steps in the production. I think we are providing the technology, and we're encouraging everyone to understand what it can do. There is a lot of growth to come in applications. Great. Thank you very much, both Artur and Cecilia. Unfortunately, the time for the Q&A session has run out. I think this will conclude the Q&A session, and I will leave it back to you, Isabelle. Thank you very much. Thank you, Ulrik, and thank you for the questions. The slide deck is already available on cellink.com, where we will also upload the recorded presentations from today. Our next interim report will be released on August 18th. In the meantime, if you have any questions or would like to reach out to Team Cellink, send us an email to ir@cellink.com. We look forward to hearing from you. We hope that you have enjoyed the CMD and thank you all for listening in. An extra warm thank you to our external speakers today, Dr. Robert Langer, A.J. Mellott, Richard Hanna, Bernard Tsui, and Ulrik Trättner for your contribution. On behalf of Team Cellink, I wish everyone a great Wednesday. Thank you and goodbye.